Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
about
CCL5-Glutamate Cross-Talk in Astrocyte-Neuron Communication in Multiple Sclerosis.Impact of siponimod on vaccination response in a randomized, placebo-controlled study.Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake.
P2860
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
@en
Siponimod
@nl
type
label
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
@en
Siponimod
@nl
prefLabel
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
@en
Siponimod
@nl
P2093
P2860
P50
P1476
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
@en
P2093
Anna Schubart
Luca Battistini
Roberta Fantozzi
P2860
P2888
P356
10.1186/S12974-016-0686-4
P50
P577
2016-08-26T00:00:00Z
P6179
1042047657